Significant Investment in Drug Delivery Innovations
PCI Pharma Services, a major name in pharmaceutical contract development and manufacturing, has announced plans to invest more than $365 million to enhance its infrastructure for the final assembly and packaging of innovative drug delivery systems. This initiative aims to improve the capabilities for drug-device combination products, with a particular focus on injectables.
Strategic Objectives and Facility Growth
This investment is part of PCI's broader strategy to meet the increasing demands of the biopharma industry, enabling them to advance complex therapies more efficiently. By expanding facilities in both Europe and the United States, PCI hopes to enhance its operations while creating opportunities for future growth, driven by newly secured contracts and commitments.
Building on Two Decades of Expertise
With over 20 years of experience in biologics, PCI possesses a deep understanding of the market and its challenges. The company’s Biotech Center of Excellence located in Philadelphia showcases this expertise, featuring advanced equipment for syringe assembly, labeling, and autoinjector assembly. Recent upgrades have introduced automation into their processes, helping PCI stay at the forefront of innovation and technology.
Expansion of Facilities in the United States
A central element of this investment is the planned expansion of PCI’s Rockford, Illinois campus, which will cover 545,000 square feet. This new facility will focus on advanced drug delivery and drug-device combination assembly in response to customer needs.
Phased Plans for Expansion
The expansion includes a substantial 475,000-square-foot project that will feature designated areas for injectable packaging and extensive warehousing. More than 20 customer suites will be available, designed for final assembly and various testing stages, all compliant with strict ISO standards.
Boosting Efficiencies in Drug Development
Additonally, PCI plans to further expand by an extra 70,000 square feet specifically for drug-device combinations to meet a variety of packaging demands. This facility will support a range of packaging technologies suitable for vials, prefilled syringes, and autoinjectors. The project is being organized in phases, with a target completion date set for late 2025.
Growing Global Presence in Europe
Simultaneously with U.S. developments, PCI is expanding its European footprint by establishing a new pharmaceutical packaging and device assembly facility in Dublin, Ireland. This site will provide extensive temperature-controlled storage solutions, with operations expected to start in late 2024.
Innovative Solutions in Dublin for Drug-Device Products
Further developments at PCI’s CityNorth Dublin campus include a new facility aimed at improving packaging and assembly capacities specifically for injectable products. This site is scheduled to be operational by mid-2025, allowing PCI to better manage cold chain requirements for biologic and injectable products through specialized temperature-controlled environments.
Dedication to Quality and Excellence
At PCI, the emphasis is on leveraging their multidisciplinary expertise to optimize production efficiency and effectiveness. With state-of-the-art equipment and dedicated services, PCI strives to offer tailored, patient-centered packaging solutions that streamline the commercialization process for drugs.
Leadership's Vision for Future Growth
CEO Salim Haffar highlighted the importance of these investments, noting, “This substantial, multi-continent investment positions PCI Pharma Services at the leading edge of the global landscape for advanced drug delivery solutions and drug-device combination product assembly.” With a steadfast commitment to meet changing market demands, PCI is focused on facilitating life-changing therapies for patients.
About PCI Pharma Services
As a leading contract development and manufacturing organization (CDMO), PCI offers integrated drug development, manufacturing, and packaging solutions that support their clients in the healthcare industry. With more than 90 successful product launches each year and over 50 years of dedicated service, PCI operates across 30 locations in seven countries, employing more than 7,000 professionals committed to delivering innovative therapies to patients. Through continued investments in technology and resources, PCI aims to meet the comprehensive needs of global drug development throughout the product lifecycle.
Frequently Asked Questions
What is the total investment amount by PCI Pharma Services?
PCI Pharma Services is investing over $365 million in its new facilities and infrastructure.
What type of products will PCI's new facilities focus on?
The new facilities will specialize in drug-device combination products and advanced drug delivery systems, mainly in injectable formats.
Where will PCI Pharma Services expand in the US?
PCI’s expansion is primarily happening at its Rockford, Illinois facility, which will undergo a 545,000-square-foot expansion.
When are the new operations expected to commence in Europe?
Operations are set to begin in Dublin, Ireland, in Q4 2024, with another facility in CityNorth Dublin expected to start in Q3 2025.
How does PCI Pharma Services ensure quality in its operations?
PCI applies advanced technology and adheres to ISO standards to ensure high-quality assembly, packaging, and testing procedures.
